Global Contract Development and Manufacturing Organization (CDMO) Outsourcing Market

Contract Development And Manufacturing Organization (CDMO) Outsourcing Market Size, Share, Growth Analysis, By Service(Contract Manufacturing Organization (CMO), Contract Research Organization (CRO) Services), By Region - Industry Forecast 2025-2032

Report ID: SQSG35J2008 | Region: Global | Published Date: February, 2024
Pages: 283 | Tables: 35 | Figures: 74

Contract Development And Manufacturing Organization (CDMO) Outsourcing Market News

  • In June 2022, a high-speed blister packaging line has been installed at Catalent's clinical supply facility in Shiga, Japan, to complement its current automated bottling line. Catalent is a global leader in empowering biopharma, cell, gene, and consumer health partners to optimize the development, launch, and supply of better patient treatments across multiple modalities.
  • In June 2022, for the treatment of individuals with moderately to highly active Crohn's disease, AbbVie said that the U.S. Food and Drug Administration (FDA) has authorized SKYRIZI (risankizumab-rzaa), the first and only selective interleukin-23 (IL-23) inhibitor (CD). 4 In two induction clinical trials and one maintenance trial, SKYRIZI significantly outperformed placebo in terms of endoscopic response (defined as a decrease of more than 50% from the baseline Simple Endoscopic Score in CD [SES-CD] or for patients with the isolated ileal disease and SES-CD of 4, at least a 2-point reduction from baseline) and clinical remission (defined as a Crohn's Disease Activity Index [CDAI] of less than 150).
$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Global Contract Development And Manufacturing Organization (CDMO) Outsourcing Market size was valued at USD 214.86 billion in 2022 and is poised to grow from USD 228.63 billion in 2023 to USD 375.84 billion by 2031, growing at a CAGR of 6.41% in the forecast period (2024-2031).

Global contract development and manufacturing organization (CDMO) outsourcing market is relatively fragmented, with a high level of competition. The prominent players operating in the market are constantly adopting various growth strategies to stay afloat in the market. Product launches, innovations, mergers, and acquisitions, collaborations and partnerships, and intensive R&D are some of the growth strategies that are adopted by these key players to thrive in the competitive market. The key market players are also constantly focused on R&D to supply industries with the most efficient and cost-effective solutions. 'Lonza Group Ltd.', 'Catalent, Inc.', 'Thermo Fisher Scientific, Inc.', 'Patheon N.V. (a part of Thermo Fisher Scientific, Inc.)', 'Cambrex Corporation', 'Recipharm AB', 'Fujifilm Holdings Corporation', 'Samsung Biologics Co., Ltd.', 'WuXi AppTec Co., Ltd.', 'Boehringer Ingelheim GmbH', 'Evonik Industries AG', 'Vetter Pharma International GmbH', 'AbbVie Contract Manufacturing', 'Jubilant Life Sciences Limited', 'Piramal Pharma Solutions', 'Almac Group Limited', 'Cytovance Biologics, Inc.', 'Ajinomoto Bio-Pharma Services', 'Grifols SA', 'Biocon Limited'

Owing to expanding acceptance of a westernized lifestyle, rising economic development, and rising population, the burden of chronic illnesses is rising significantly over the world. About 133 million Americans suffer from chronic illnesses, accounting for more than 40% of the nation's population and being typically incurable and continuous. It is anticipated that by 2020, there would be 157 million people worldwide, 81 million of whom will have various illnesses. Around 8% of children aged 5 to 17 reported having limited activities because of at least one chronic illness or impairment, while around 50% of adults report having a chronic condition.

Currently, the contract development and manufacturing organization outsourcing market is fragmented. The necessity for quick innovations to provide efficient process solutions to improve the drug development process has increased among pharmaceutical businesses. Many contract development and manufacturing businesses are preferring to combine with small and major pharma & biotech enterprises, along with many life-science corporations, in order to improve their service offerings.

The market in North America is distinguished by the region's long-standing CDMO presence. Along with this element, expanding partnerships between pharmaceutical firms and CDMOs providing a wide variety of services are to blame for the region's leading market share globally. The pharmaceutical business is supported by an estimated 300 pharmaceutical contract development and manufacturing companies (CDMOs). The industry is still incredibly fragmented despite rising merger and acquisition (M&A) activity; the top five CDMOs account for only 15% of the market as a whole.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

Click here right-arrow
logo-images

Related Reports

Regulatory Affairs Outsourcing Market
Buy Now GET FREE SAMPLE
Procurement Outsourcing Market
Buy Now GET FREE SAMPLE
Engineering Services Outsourcing Market
Buy Now GET FREE SAMPLE
Business Process Outsourcing Market
Buy Now GET FREE SAMPLE
Contract Research Organization Market
Buy Now GET FREE SAMPLE
Medical Affairs Outsourcing Market
Buy Now GET FREE SAMPLE
Knowledge Process Outsourcing Market
Buy Now GET FREE SAMPLE
Healthcare IT Outsourcing Market
Buy Now GET FREE SAMPLE

Feedback From Our Clients

Global Contract Development and Manufacturing Organization (CDMO) Outsourcing Market

Report ID: SQSG35J2008

$5,300
BUY NOW GET FREE SAMPLE